Sunshine Biopharma, Inc.
SBFM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | – | $9,410 | $8,901 | $9,595 |
| % Growth | – | 5.7% | -7.2% | – |
| Cost of Goods Sold | – | $5,987 | $6,171 | $6,502 |
| Gross Profit | – | $3,423 | $2,730 | $3,093 |
| % Margin | – | 36.4% | 30.7% | 32.2% |
| R&D Expenses | – | $196 | $215 | -$785 |
| G&A Expenses | – | $3,833 | $3,238 | $4,604 |
| SG&A Expenses | – | $4,034 | $3,636 | $4,807 |
| Sales & Mktg Exp. | – | $202 | $398 | $203 |
| Other Operating Expenses | – | $1,247 | $175 | $1,109 |
| Operating Expenses | – | $5,478 | $4,026 | $5,131 |
| Operating Income | – | -$2,055 | -$1,296 | -$2,038 |
| % Margin | – | -21.8% | -14.6% | -21.2% |
| Other Income/Exp. Net | – | $75 | $76 | -$249 |
| Pre-Tax Income | – | -$1,980 | -$1,220 | -$2,287 |
| Tax Expense | – | -$209 | -$40 | -$129 |
| Net Income | – | -$1,771 | -$1,180 | -$2,158 |
| % Margin | – | -18.8% | -13.3% | -22.5% |
| EPS | – | -7.8 | -0.44 | -0.84 |
| % Growth | – | -1,672.7% | 47.6% | – |
| EPS Diluted | – | -7.8 | -0.44 | -0.84 |
| Weighted Avg Shares Out | – | 225 | 2,703 | 2,580 |
| Weighted Avg Shares Out Dil | – | 225 | 2,703 | 2,580 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $73 | $75 | $99 |
| Interest Expense | – | $0 | $0 | $9 |
| Depreciation & Amortization | – | $73 | $65 | $65 |
| EBITDA | – | -$1,907 | -$1,155 | -$2,213 |
| % Margin | – | -20.3% | -13% | -23.1% |